Report Misleads on Drug Prices

Blog

The Pharmaceutical Research and Manufacturers of America (PhRMA) released yet another report designed to obfuscate the issue of sky-rocketing drug prices. Once again, PhRMA turned its sights on hospitals in just another example of PhRMA choosing to blame others rather than looking inward at the... read more

Topic: Access and Coverage
Tag: drug prices

Senate HELP committee holds hearing on cost of prescription drugs

AHA News Now

The Senate Committee on Health, Education, Labor and Pensions today held the second in a series of hearings on the cost of prescription drugs. “We have to make more progress to get at the root of the problem facing patients, which is the high prices set by drug manufacturers,” Committee Ranking Member... read more

Topic: Access and Coverage
Tag: drug prices

AHA Stat Blog: Report misses mark on 340B program

AHA News Now

The latest report from a group financed and backed by the pharmaceutical industry “continues to misrepresent” the 340B Drug Pricing Program and its “successful 25-year history of helping hospitals stretch scarce financial resources to expand and improve access to lifesaving prescription drugs and... read more

Topic: Access and Coverage
Tags: 340B, Drug Pricing Program, access, drug prices

CMS projects Part D monthly premium to decline slightly in 2018

AHA News Now

The average monthly premium for a basic Medicare Part D prescription drug plan in 2018 is estimated to be $33.50 per month – or approximately $1.20 less than the average premium in 2017 – the Centers for Medicare & Medicaid Services announced last week. The projection is based on bids submitted by drug... read more

Topic: Access and Coverage
Tag: drug prices

Express Scripts reports on 2016 drug spending by health plan clients

AHA News Now

Drug spending per member for public health insurance exchange plans sponsored by Express Scripts clients increased 14% in 2016, driven by increases in both unit costs and use, according to a new report by the pharmacy benefit management company. Drug spending per member for Medicaid, Medicare Part D, and... read more

Topic: Access and Coverage
Tag: drug prices

Hospitals, not pharmaceutical manufacturers, are preserving and protecting the safety net

Blog

A group financed by the pharmaceutical industry is hosting a meeting today on the 340B Drug Pricing Program with the goal of “Preserving the True Safety Net.” But what the meeting really will be about is the pharmaceutical industry – with their skyrocketing prescription drug prices and huge profits –... read more

Topic: Access and Coverage
Tags: 340B, Drug Pricing Program, Community benefit, access, drug prices

Changing 340B is the wrong prescription for addressing skyrocketing pharmaceutical costs

Blog

The rapidly rising costs of prescription drugs is causing significant financial challenges for patients and their care providers.

Many groups, including the AHA, are evaluating options for addressing this important issue. However, one recent proposal, which is seriously misguided, would reduce a program... read more

Topic: Access and Coverage
Tags: 340B, Drug Pricing Program, access, price, drug prices

Stop Unsustainable Drug Prices

Blog

Today’s New York Times provides arguments from drug companies justifying the excessive jump in pharmaceutical prices in recent years, saying the higher prices won’t impact patients. 

Hospitals’ top priority is providing patients with safe and effective care, but the skyrocketing costs of pharmaceuticals... read more

Topic: Access and Coverage
Tags: access, price, drug prices

Protect Patients. Preserve 340B.

Blog

More than 20 years ago, Congress created the 340B Drug Pricing Program to allow eligible hospitals and health systems to stretch limited resources and expand access to care for vulnerable patients. But despite a proven track record of increasing patient access to vital medical services and decreasing... read more

Topic: Access and Coverage
Tags: 340B, Drug Pricing Program, access, price, drug prices

340B Proposals Would Jeopardize Hospitals' Ability to Serve Vulnerable Patients

Blog

The 340B Drug Pricing Program has a strong track record of helping to combat high prescription drug prices and increase access to vital medicines and comprehensive health care services for our nation’s most vulnerable individuals.

However, we are concerned that recent policy changes proposed by the... read more

Topic: Access and Coverage
Tags: 340B, Drug Pricing Program, drug prices

Keyword Search

Date